Designing a ‘base paint’ to fight cancer
Immunocore is harnessing the body’s own immune cells to fight cancer. The biotechnology underpinning Immunocore is based on the science of founder Dr Bent Jakobsen, who led his own research team at Oxford’s Institute of Molecular Medicine until 2000. That work is now paying dividends, with positive results for their first clinical trials recently announced. Immunocore’s ambition is to become a premier global biotechnology company and a leader in the field of cancer immunotherapy. The UK’s excellent science base supports companies across industrial sectors to innovate, bringing broad benefits for society and supporting economic growth. A collection of stories about businesses using science in the UK, 'Inspiring innovations' is available to read on the Royal Society website:
